RECOVERY trial results demonstrate baricitinib reduces deaths in hospitalised COVID-19 patients

• BenevolentAI first identified baricitinib as a potential COVID-19 treatment in January 2020 and published its hypothesis in The Lancet and in The Lancet Infectious Diseases

• The RECOVERY data adds to the growing body of evidence from nine clinical trials across 12,000 patients in which the use of baricitinib (or another JAK inhibitor) was found to reduce deaths in hospitalised COVID-19 patients by approximately one-fifth (rate ratio 0.80, 95% CI 0.71 to 0.89; p<0.001)

London, 4 March 2022, The University of Oxford team running the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which recruited over 4,000 patients, have announced that treatment with baricitinib reduces deaths in patients hospitalised with COVID-19 by 13% (rate ratio 0.87, 95% CI 0.77 to 0.98; p=0.026). The benefit was greatest in those seriously ill and additive to that of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients.

Dr Anne Phelan, Chief Scientific Officer at BenevolentAI, commented: “This story started with our novel AI-derived hypothesis, which quickly led to unprecedented global scientific collaboration from public, private and non-profit organisations around the world. Each has played their part in bringing this game-changing discovery to patients. Today that story comes full circle, with another life-saving COVID-19 treatment added to the clinical armamentarium, further validating our hypothesis. The significance of this spans beyond COVID-19: it demonstrates that our technology can fundamentally transform the way we understand disease biology and help uncover new treatment approaches for thousands of diseases.” 

RECOVERY is one of nine clinical trials of baricitinib and similar drugs (known as JAK inhibitors) for the treatment of COVID-19. Across these nine trials, which involve around 12,000 patients, the use of baricitinib (or another JAK inhibitor) was found to reduce deaths in hospitalised COVID-19 patients by approximately one-fifth. In the RECOVERY trial, baricitinib also increased the chances of patients being discharged alive within 28 days and reduced the risk of their condition worsening.

BenevolentAI first identified baricitinib as a potential COVID-19 treatment in January 2020, and published this research in The Lancet and in The Lancet Infectious Diseases. The company’s scientists used its AI platform and biomedical Knowledge Graph to search for already approved drugs that could both inhibit viral entry into cells, and deliver an anti-inflammatory effect to reduce the body’s extreme immune response known as the cytokine storm. Baricitinib, an oral JAK inhibitor, owned by Eli Lilly and approved for rheumatoid arthritis, was identified as the most promising treatment from a list of thousands of potential drugs. During a 48 hour accelerated search process, the team uncovered baricitinib’s previously unknown anti-viral properties, in addition to its already known anti-inflammatory effects. 

BenevolentAI’s research sparked global trials of baricitinib to treat COVID-19, such as the NIAID ACTT-II. Eli Lilly’s placebo-controlled trial, COV-BARRIER, showed baricitinib reduced deaths in hospitalised COVID-19 patients by 38%. Baricitinib has been strongly recommended by the World Health Organisation (WHO) at its highest evidence level in the BMJ Living Review. It has been authorised for emergency use as a solo treatment for hospitalised patients by the FDA, or in combination with remdesivir.

About BenevolentAI

BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track-record of scientifically validated discoveries. The BenevolentAI PlatformTM powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

More Posts

You Might Also Like

BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022